Effect of Roflumilast, a Selective PDE4 Inhibitor, on Bone Phenotypes in ADO2 Mice

Area of Science:

• Bone Biology and Disease
• Genetics and Rare Diseases
• Pharmacology and Therapeutics

Background:

• Autosomal Dominant Osteopetrosis type II (ADO2) is a rare genetic bone disorder characterized by impaired osteoclast function, often caused by CLCN7 gene mutations.
• Mouse models carrying common human ADO2 mutations phenocopy the human disease, providing a platform for therapeutic investigation.
• Roflumilast (RF), a phosphodiesterase 4 (PDE4) inhibitor, is known to modulate the cAMP pathway and has shown potential to increase osteoclast activity.

Purpose of the Study:

• To investigate the therapeutic potential of roflumilast (RF) in rescuing bone phenotypes in a mouse model of Autosomal Dominant Osteopetrosis type II (ADO2).
• To evaluate the effects of RF on bone mineral density, bone micro-architecture, and serum bone biomarkers in ADO2 mice.

Main Methods:

• Mice with a common ADO2 mutation (p.G213R) were fed diets containing 0, 20, or 100 mg/kg of RF for six months.
• Bone mineral density (aBMD) and bone micro-architecture were assessed longitudinally using in vivo DXA and micro-CT.
• Serum levels of bone turnover biomarkers, including CTX, TRAP, and P1NP, were measured at specified time points.

Main Results:

• RF treatment did not significantly improve whole body, femur, or spine aBMD in ADO2 mice compared to controls.
• No significant improvements in trabecular bone volume fraction (BV/TV) in the distal femur were observed with RF administration.
• Serum bone biomarker levels remained unchanged, indicating no significant effect of RF on bone resorption or formation markers in this model.

Conclusions:

• Roflumilast (RF) does not appear to rescue the osteopetrotic bone phenotypes in heterozygous ADO2 mice.
• The in vitro observation of increased osteoclast activity by RF was not translated into a therapeutic benefit in vivo for ADO2.
• Further research may be needed to explore alternative therapeutic strategies for Autosomal Dominant Osteopetrosis type II.